{"id":2688,"date":"2026-08-25T09:00:00","date_gmt":"2026-08-25T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2688"},"modified":"2026-08-25T19:45:02","modified_gmt":"2026-08-25T23:45:02","slug":"fda-extends-deramiocel-review-to-november-22-after-major-amendment","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2688","title":{"rendered":"FDA Extends Deramiocel Review to November 22 After Major Amendment"},"content":{"rendered":"

Company:<\/strong> Capricor Therapeutics · Asset:<\/strong> Deramiocel · Indication:<\/strong> Duchenne Muscular Dystrophy · Event Type:<\/strong> PDUFA Date Extension · Date:<\/strong> August 24, 2026<\/p>\n

\"20260825_Capricor_Therapeutics_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

FDA extended the PDUFA target action date for Capricor’s deramiocel BLA from August 22 to November 22, 2026, after the company submitted a major amendment. The amendment adds 24-month open-label extension data from Phase III HOPE-3, robustness analyses and a refined proposed indication centered on upper-limb function. Acceptance of a major amendment preserves active review but is not evidence that approval, label scope or benefit-risk conclusions are favorable.<\/p>\n

What Happened<\/h4>\n

Deramiocel is an allogeneic cardiosphere-derived cell product under review for Duchenne muscular dystrophy. Capricor says HOPE-3 met its primary upper-limb endpoint and that the additional follow-up supports preservation of function, though the new disclosure does not provide the 24-month numerical results, missing-data assumptions, sensitivity analyses or the exact proposed label wording. FDA’s Center for Biologics Evaluation and Research accepted the amendment and classified it as major, adding three months for review; the company says CBER cited significant unmet need. Regulatory acceptance means the material will be evaluated, not that the analyses are endorsed or that questions raised during the July advisory-committee process are resolved. The product consists of donor-derived cardiac cells proposed to act largely through secreted extracellular vesicles with immunomodulatory and antifibrotic effects; it does not restore dystrophin, which makes functional durability, lot comparability, dose consistency and mechanistic attribution central to review.<\/p>\n

Deep Analysis<\/h4>\n

A constructive interpretation is that longer follow-up and label refinement give FDA a reviewable route focused on the endpoint with the strongest evidence. A cautious interpretation is that the new analysis and narrower framing are needed because the original package left material uncertainty. The extension alone cannot distinguish between these explanations. Open-label extension data can inform durability and safety, but lack a concurrent control and are vulnerable to attrition, survivor bias, treatment exposure differences and functional assessment variability; robustness analyses are most persuasive when prespecified and stable across reasonable assumptions, details that are not yet public.<\/p>\n

Competitive significance depends on whether the final label, if any, covers a clinically meaningful population and whether repeated intravenous cell dosing produces durable function with reliable manufacturing. Approval would create a differentiated non-gene-replacement option in DMD; delay does not validate that outcome either way.<\/p>\n

Company and Product Background<\/h4>\n

Capricor Therapeutics develops deramiocel, formerly CAP-1002, for Duchenne muscular dystrophy. DMD is caused by pathogenic DMD variants and progressive loss of dystrophin, leading to skeletal, respiratory and cardiac decline. Deramiocel is intended to modulate inflammation and fibrosis rather than repair the causal gene. For a living-cell product, clinical translation depends on donor-cell consistency, expansion and release assays, potency correlation, infusion safety, immune response, dose interval, functional endpoint reliability and durability; extracellular-vesicle signaling is a plausible mechanism but does not by itself establish patient benefit.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Regulatory Timing<\/td>\nPDUFA moved from August 22 to November 22, 2026<\/td>\n<\/tr>\n
Major Amendment<\/td>\n24-month extension data, robustness analyses, refined upper-limb indication<\/td>\n<\/tr>\n
Clinical Basis<\/td>\nCompany reports HOPE-3 met the upper-limb primary endpoint (numerical data undisclosed)<\/td>\n<\/tr>\n
Mechanism\/CMC<\/td>\nAllogeneic cardiac-derived cells; paracrine immunomodulatory hypothesis, not dystrophin restoration<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A narrower, upper-limb-focused indication built on longer follow-up gives FDA a more reviewable package, and CBER’s acceptance plus cited unmet need keep deramiocel on an active, if delayed, path to a decision.<\/p>\n

Bear case:<\/strong> A major amendment three months before the original PDUFA date, following a negative July advisory-committee vote, suggests the original package left real gaps that open-label, uncontrolled extension data may not fully resolve.<\/p>\n

InSilens Take<\/h4>\n

The decisive fact here is timing, not sentiment: deramiocel remains under active review with a new November 22 target date. Neither the extension nor CBER’s acceptance of the amendment should be read as a signal about the eventual approval decision, given that the underlying 24-month numerical data and exact label language remain undisclosed.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> High on facts, Moderate-Low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA extended the PDUFA target action date for Capricor’s deramiocel BLA from August 22 to November 22, 2026, after the company submitted a major amendment. The amendment adds 24-month open-label extension data from Phase…<\/p>\n","protected":false},"author":1,"featured_media":2695,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[210,428,84],"class_list":["post-2688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-capricor-therapeutics","tag-deramiocel","tag-duchenne-muscular-dystrophy"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2688"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2688\/revisions"}],"predecessor-version":[{"id":2700,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2688\/revisions\/2700"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2695"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}